Phaseline

Companies › Reviva Pharmaceuticals

Reviva Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Brilaroxazine (RP5063)
Dopamine D2 receptor partial agonist and serotonin 5-HT1A receptor partial agonist
DRD2, HT1APhase 3Schizophrenia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05184335Brilaroxazine (RP5063)Phase 3SchizophreniaPsychiatryFeb 2025

From the company's SEC filings

Cash of $20m on 2026-06-30; operating cash outflow about $12m a year; runway about 20 months at that burn, to Feb 2028

Press releases filed as 8-K in the last year:

Targets

DRD2 (1) HT1A (1)

Companies with the same targets

Prilenia Changchun GeneScience Pharmaceutical Vanda Pharmaceuticals Intra-Cellular Therapies LB Pharmaceuticals Sichuan Kelun Pharmaceutical Gedeon Richter Jazz Pharmaceuticals Serina Therapeutics Boryung Pharmaceutical

Companies built like this

LB Pharmaceuticals Gedeon Richter Minerva Neurosciences VistaGen Therapeutics Curemark

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.